alexa Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).
Oncology

Oncology

Journal of Oncology Research and Treatment

Author(s): Camidge DR, Iafrate AJ, Shaw AT, Kwak EL, Bang Y

Abstract Share this page

Background: The anaplastic lymphoma kinase (ALK) fusion gene is a key oncogenic driver in a subset of patients with NSCLC. Crizotinib is a potent and selective, ATP-competitive, small molecule ALK inhibitor. Patients with ALK-positive NSCLC may benefit from targeted ALK inhibitors. Methods: An ongoing open-label, multicenter, 2-part, phase I trial is investigating the safety, tolerability, pharmacokinetics, and antitumor activity of crizotinib in patients with advanced cancer. Updated safety and response data and preliminary PFS data from an expanded ALK-positive cohort of patients with NSCLC in part 2 of the study are reported. Patients received oral crizotinib 250 mg BID in 28-day cycles. Results: Currently, 119 patients with ALK-positive NSCLC have enrolled and 116 are evaluable for response, with 94 in follow-up for survival. Median age was 51 years; patients were usually never- or former-smokers (99%) with adenocarcinoma histology (97%). Most patients were heavily pretreated, with 44% receiving ≥3 prior treatments. At a median follow-up of 11 months (95% CI: 9.2, 12.8 months), ORR was 61% (95% CI: 52%, 70%), including 2 CRs and 69 PRs, and clinical benefit rate (CR+PR+SD) was 88%. Responses (CR or PR) were rapid (median 8 weeks to response). Preliminary median response duration estimate was 48 weeks (95% CI: 36 weeks, not reached). Preliminary median PFS was 10 months (95% CI: 8, 15 months). Median OS has not been reached. Treatment-related AEs were mostly Grade 1/2 with vision disorder (63%) and GI events (nausea, 54%; diarrhea, 49%; vomiting, 40%) the most common. These AEs typically had an early onset (Cycle 1) and diminished as treatment continued. Conclusions: In patients with ALK-positive NSCLC, the efficacy of crizotinib was robust, rapid, durable and clinically meaningful. The most common AEs with crizotinib were either self-limiting or easily managed. Crizotinib may offer a new standard of care for patients with ALK-positive advanced NSCLC, a subgroup that currently lacks any approved agent specific to the molecular diagnosis.

  • To read the full article Visit
  • Subscription
This article was published in ASC University and referenced in Journal of Oncology Research and Treatment

Relevant Expert PPTs

Relevant Speaker PPTs

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords